Related Experiment Video
Updated: Jul 6, 2026
09:56
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Liposomal doxorubicin: a phase II trial
Giancarlo Balbi1, Serena Visconti, Antonietta Monteverde
1Department Obstetrics and Gynecology, Second University of Study of Naples, Naples, Italy. giancarlo.balbi@unina2.it
Acta Bio-Medica : Atenei Parmensis
|March 12, 2008
Summary
Liposomal doxorubicin shows similar efficacy to doxorubicin for advanced endometrial cancer but with reduced heart toxicity. This study evaluated its use as a first-line treatment in women with disseminated disease.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Doxorubicin is a standard treatment for disseminated endometrial carcinoma.
- Liposomal doxorubicin offers a potentially safer alternative with reduced cardiotoxicity.
Purpose of the Study:
- To evaluate the efficacy and safety of liposomal doxorubicin as a first-line therapy for disseminated endometrial carcinoma.
Main Methods:
- A phase II clinical trial was conducted with 22 patients.
- Patients received liposomal doxorubicin (40 mg/m2) intravenously every 4 weeks.
- Treatment continued until disease progression or unacceptable toxicity.
Main Results:
- 36% of patients achieved tumor regression (3 complete, 5 partial responses).
- 46% had stable disease, and 18% experienced disease progression.
- Common adverse events included fatigue, anemia, pain, and dermatologic toxicity.
Conclusions:
- Liposomal doxorubicin demonstrates comparable response rates to conventional doxorubicin.
- It exhibits a favorable safety profile, particularly regarding cardiac toxicity, in this patient population.
